Page last updated: 2024-11-05

fomblin y 04

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

fomblin Y 04: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13350568
SCHEMBL ID198
MeSH IDM0071510

Synonyms (15)

Synonym
1,1,1,2,3,3-hexakis(fluoranyl)propan-2-ol
A844141
1,1,1,2,3,3-hexafluoro-2-propanol
hexafluoro-2-propylalcohol
fomblin y-04
fomblin y 04
AKOS015995331
SCHEMBL198
33701-74-5
AMY3633
nmfqpfsipwzzmr-uhfffaoysa-n
hexafluoro-i-propanol
hexafluoropropan-2-ol
DTXSID301300789
85592-84-3

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Because the possible toxicological relevance of the temporarily increased motor activity observed in 1000 mg/kg/d males could not be excluded, these changes were considered possibly adverse in nature."( A Combined 28-Day Oral Toxicity Study of HFPO-Amidol (CASRN 75888-49-2) With Reproductive/Developmental Toxicity Screening Test in Wistar Han Rats.
Bagley, BD; Hakes, DC; Hope, EF; Moilanen, LH; Reynolds, JE; van Otterdijk, F,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" The changes observed in female rats were considered not treatment related in the absence of a dose-response trend."( A Combined 28-Day Oral Toxicity Study of HFPO-Amidol (CASRN 75888-49-2) With Reproductive/Developmental Toxicity Screening Test in Wistar Han Rats.
Bagley, BD; Hakes, DC; Hope, EF; Moilanen, LH; Reynolds, JE; van Otterdijk, F,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]